April 27, 2015.
Reuters reported Friday
that shares in French drug maker Innate Pharma surged to a record high - increasing by as much as 57 percent to €14 euros on volumes of 10.7 million shares - following its deal with AstraZeneca to accelerate and broaden development of its immune-boosting anti-cancer medicines. Innate will receive an initial payment of $250 million from AstraZeneca, which is collaborating with Medimmune to develop the French firm's anti-NKG2A antibody, IPH2201 aimed at stimulating the body's immune system to destroy cancer cells. Reuters reports that "it is the most significant transaction ever by the Marseille-based biopharmaceutical company, worth about €700 million on the stock market even after Friday's share price jump".
http://www.medicaldaily.com/astrazeneca-drug-deal-hoists-innate-pharma-shares-record-high-330646
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.
2 Commerce Drive
Cranbury, NJ 08512